Prednisolone Acetate

Modify Date: 2024-01-02 12:43:45

Prednisolone Acetate Structure
Prednisolone Acetate structure
Common Name Prednisolone Acetate
CAS Number 52-21-1 Molecular Weight 402.481
Density 1.3±0.1 g/cm3 Boiling Point 579.8±50.0 °C at 760 mmHg
Molecular Formula C23H30O6 Melting Point 240-244 °C
MSDS Chinese USA Flash Point 198.4±23.6 °C
Symbol GHS06
GHS06
Signal Word Danger

 Use of Prednisolone Acetate


Prednisolone 21-acetate is an adrenal cortico hormones, with anti-inflammatory, anti-allergic and immune suppressive effects.

 Names

Name Prednisolone Acetate
Synonym More Synonyms

 Prednisolone Acetate Biological Activity

Description Prednisolone 21-acetate is an adrenal cortico hormones, with anti-inflammatory, anti-allergic and immune suppressive effects.
Related Catalog

 Chemical & Physical Properties

Density 1.3±0.1 g/cm3
Boiling Point 579.8±50.0 °C at 760 mmHg
Melting Point 240-244 °C
Molecular Formula C23H30O6
Molecular Weight 402.481
Flash Point 198.4±23.6 °C
Exact Mass 402.204254
PSA 100.90000
LogP 2.58
Vapour Pressure 0.0±3.7 mmHg at 25°C
Index of Refraction 1.587
Storage condition 2-8°C
Stability Stable. Incompatible with strong oxidizing agents.

 MSDS


Section 1. Chemical Product and Company Identification
Prednisolone acetateCatalog
YY1423, P1219, PR100
Common Name/
Number(s).
Trade Name
CAS#52-21-1
Manufacturer
RTECSTU4152500
SPECTRUM CHEMICAL MFG. CORP.
TSCATSCA 8(b) inventory:
Prednisolone acetate
Commercial Name(s)Prednisolone 21-Acetate; Cormalone; Cortpred; Meticortelone
CI#Not available.
acetate; Nisolone; Prediacortine; Perdicort
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione acetate
Synonym
IN CASE OF EMERGENCY
Chemical Name
(11.beta.)-
Chemical FamilyNot available.CALL (310) 516-8000
Chemical FormulaC21H26O5
SPECTRUM CHEMICAL MFG. CORP.

Section 2.Composition and Information on Ingredients
Exposure Limits
TWA (mg/m3)STEL (mg/m3) CEIL (mg/m3)
NameCAS #% by Weight
1) Prednisolone acetate52-21-1100
Not applicable.
Toxicological Data
on Ingredients

Section 3. Hazards Identification
Potential Acute Health Effects Slightly hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of inhalation.
CARCINOGENIC EFFECTS: Not available.
Potential Chronic Health
EffectsMUTAGENIC EFFECTS: Not available.
TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Classified Reproductive system/toxin/female, Reproductive system/toxin/male
[POSSIBLE].
Repeated or prolonged exposure is not known to aggravate medical condition.
Prednisolone acetate

Section 4. First Aid Measures
Eye ContactCheck for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at
least 15 minutes. Get medical attention if irritation occurs.
Skin ContactWash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops.
Serious Skin ContactNot available.
InhalationIf inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get
medical attention.
Serious InhalationNot available.
IngestionDo NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an
unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight
clothing such as a collar, tie, belt or waistband.
Serious IngestionNot available.

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Flash PointsNot available.
Flammable LimitsNot available.
Products of CombustionThese products are carbon oxides (CO, CO2).
Fire Hazards in Presence of Slightly flammable to flammable in presence of heat.
Various Substances
Explosion Hazards in Presence Risks of explosion of the product in presence of mechanical impact: Not available.
Risks of explosion of the product in presence of static discharge: Not available.
of Various Substances
SMALL FIRE: Use DRY chemical powder.
Fire Fighting Media
and InstructionsLARGE FIRE: Use water spray, fog or foam. Do not use water jet.
Not available.
Special Remarks on
Fire Hazards
Special Remarks on Explosion Not available.
Hazards

Section 6. Accidental Release Measures
Small SpillUse appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by
spreading water on the contaminated surface and dispose of according to local and regional authority
requirements.
Large SpillUse a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water
on the contaminated surface and allow to evacuate through the sanitary system.
Prednisolone acetate

Section 7. Handling and Storage
PrecautionsKeep away from heat. Keep away from sources of ignition. Ground all equipment containing material. Do not
breathe dust.
StorageKeep container tightly closed. Keep container in a cool, well-ventilated area.

Section 8. Exposure Controls/Personal Protection
Engineering ControlsUse process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal Protection
Safety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case of Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used
a Large Spillto avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist
BEFORE handling this product.
Exposure LimitsNot available.

Section 9. Physical and Chemical Properties
Physical state and appearance Solid. (Solid crystalline powder.)OdorOdorless.
TasteNot available.
Molecular Weight402.49 g/mole
ColorWhite.
pH (1% soln/water)Not available.
Boiling PointNot available.
Melting PointDecomposes. (237°C or 458.6°F)
Critical TemperatureNot available.
Not available.
Specific Gravity
Vapor PressureNot applicable.
Vapor DensityNot available.
VolatilityNot available.
Odor ThresholdNot available.
Not available.
Water/Oil Dist. Coeff.
Ionicity (in Water)Not available.
See solubility in water, methanol, acetone.
Dispersion Properties
SolubilitySoluble in methanol, acetone.

Section 10. Stability and Reactivity Data
StabilityThe product is stable.
Not available.
Instability Temperature
Conditions of InstabilityNot available.
Incompatibility with variousNot available.
substances
CorrosivityNon-corrosive in presence of glass.
Prednisolone acetate
Special Remarks onNot available.
Reactivity
Special Remarks onNot available.
Corrosivity
PolymerizationNo.

Section 11. Toxicological Information
Routes of EntryInhalation. Ingestion.
Toxicity to AnimalsLD50: Not available.
LC50: Not available.
Chronic Effects on Humans Not available.
Other Toxic Effects onSlightly hazardous in case of skin contact (irritant), of ingestion, of inhalation.
Humans
Special Remarks onNot available.
Toxicity to Animals
Special Remarks on
May cause adverse reproductive effects and birth defects (teratogenic).
Chronic Effects on Humans
Excreted in maternal milk in human.
Special Remarks on otherAcute Potential Health Effects:
Toxic Effects on HumansSkin: May cause skin irritation. It may be absorbed through the skin.
Eyes: Dust may cause eye irritation.
Inhalation: Dust may cause respiratory tract irritation.
Ingestion: May cause gastrointestinal tract irritation. May also affect behavior (toxic psychosis), metabolism
(anorexia), and urinary system. This material is readily absorbed from the gastrointestinal tract. Ingestion of a
massive single dose is unlikely to cause adverse effects.
Chronic Potential Health Effects:
Prolonged or repeated exposure by inhalation, ingestion, or skin contact may cause allergic reaction (possible
hypersensitization).
Other symptoms of chronic overdose effects may include, acne or other skin problems, weight loss or weight
gain, hip or shoulder pain, fullness in face, fluid retention associated with sodium retention, potassium
loss,swelling of feet or lower legs, excess or abnormal thirst, menstrual irregularities, nausea, vomiting, irregular
heartbeat, muscle cramps, weakness, osteoporosis, increased susceptibility to infection, psychosis, and eye
problems. May also affect urinary system (polyuria), liver, adrenal gland.

Section 12. Ecological Information
EcotoxicityNot available.
BOD5 and CODNot available.
Products of BiodegradationPossibly hazardous short term degradation products are not likely. However, long term degradation products may
arise.
The product itself and its products of degradation are not toxic.
Toxicity of the Products
of Biodegradation
Special Remarks on theNot available.
Products of Biodegradation

Section 13. Disposal Considerations
Waste DisposalWaste must be disposed of in accordance with federal, state and local environmental
control regulations.
Prednisolone acetate

Section 14. Transport Information
DOT ClassificationNot a DOT controlled material (United States).
IdentificationNot applicable.
Not applicable.
Special Provisions for
Transport
DOT (Pictograms)

Section 15. Other Regulatory Information and Pictograms
TSCA 8(b) inventory: Prednisolone acetate
Federal and State
Regulations
CaliforniaCalifornia prop. 65: This product contains the following ingredients for which the State of California has found
to cause cancer which would require a warning under the statute: No products were found.
Proposition 65
Warnings
California prop. 65: This product contains the following ingredients for which the State of California has found
to cause birth defects which would require a warning under the statute: No products were found.
Other RegulationsEINECS: This product is on the European Inventory of Existing Commercial Chemical Substances (EINECS No.
200-134-1).
Canada: Listed on Canadian Domestic Substance List (DSL).
China: Not listed on National Inventory.
Japan: Not listed on National Inventory (ENCS).
Korea: Listed on National Inventory (KECI).
Philippines: Mot listed on National Inventory (PICCS).
Australia: Listed on AICS.
WHMIS (Canada) CLASS D-2A: Material causing other toxic effects (VERY TOXIC).
Other Classifications
DSCL (EEC)
R62- Possible risk of impaired fertility.S36- Wear suitable protective clothing.
R63- Possible risk of harm to the
unborn child.
Health Hazard
HMIS (U.S.A.)1 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
1 0 Reactivity
Health
Reactivity
0
Specific hazard
Personal Protection
E
WHMIS (Canada)
(Pictograms)
DSCL (Europe)
(Pictograms)
TDG (Canada)
(Pictograms)
Prednisolone acetate
ADR (Europe)
(Pictograms)
Protective Equipment
Gloves.
Lab coat.
Dust respirator. Be sure to use an
approved/certified respirator or
equivalent. Wear appropriate respirator
when ventilation is inadequate.


SECTION 16 - ADDITIONAL INFORMATION
N/A

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TU4152500
CHEMICAL NAME :
Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-, 21-acetate
CAS REGISTRY NUMBER :
52-21-1
BEILSTEIN REFERENCE NO. :
3111798
LAST UPDATED :
199612
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C23-H30-O6
MOLECULAR WEIGHT :
402.53
WISWESSER LINE NOTATION :
L E5 B666 OV AHTTT&J A1 CQ E1 FV1OV1 FQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>240 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,713,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
3500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,713,1982 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1800 mg/kg
SEX/DURATION :
female 2-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - abortion
REFERENCE :
FESTAS Fertility and Sterility. (American Fertility Soc., 608 13th Ave. S, Birmingham, AL 35282) V.1- 1950- Volume(issue)/page/year: 22,735,1971
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
96 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
REFERENCE :
SEIJBO Senten Ijo. Congenital Anomalies. (Nippon Senten Ijo Gakkai, c/o Kinki Daigaku Igakubu Kaibagaku Kyoshitsu, 380 Nishiyama, Sayama-cho, Mirami-Kawachi-gun, Osaka-fu, Japan) V.1-26, 1960-86. For publisher information, see CGANE7. Volume(issue)/page/year: 13,245,1973
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
96 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
REFERENCE :
SEIJBO Senten Ijo. Congenital Anomalies. (Nippon Senten Ijo Gakkai, c/o Kinki Daigaku Igakubu Kaibagaku Kyoshitsu, 380 Nishiyama, Sayama-cho, Mirami-Kawachi-gun, Osaka-fu, Japan) V.1-26, 1960-86. For publisher information, see CGANE7. Volume(issue)/page/year: 13,245,1973 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X1855 No. of Facilities: 8 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 138 (estimated) No. of Female Employees: 130 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3752 No. of Facilities: 30 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 726 (estimated) No. of Female Employees: 429 (estimated)

 Safety Information

Symbol GHS06
GHS06
Signal Word Danger
Hazard Statements H300
Precautionary Statements Missing Phrase - N15.00950417
Personal Protective Equipment Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
Hazard Codes T:Toxic
Risk Phrases R25
Safety Phrases S45
RIDADR UN 2811 6.1/PG 3
WGK Germany 3
RTECS TU4152500
HS Code 2937210000

 Synthetic Route

~%

Prednisolone Acetate Structure

Prednisolone Acetate

CAS#:52-21-1

Literature: Hogg et al. Journal of the American Chemical Society, 1955 , vol. 77, p. 4436

~%

Prednisolone Acetate Structure

Prednisolone Acetate

CAS#:52-21-1

Literature: The Upjohn Company Patent: US5426198 A1, 1995 ;

~%

Prednisolone Acetate Structure

Prednisolone Acetate

CAS#:52-21-1

Literature: Herzog et al. Journal of the American Chemical Society, 1955 , vol. 77, p. 4781,4783

~%

Prednisolone Acetate Structure

Prednisolone Acetate

CAS#:52-21-1

Literature: Florey; Restivo Journal of Organic Chemistry, 1957 , vol. 22, p. 406,408

 Customs

HS Code 2937210000

 Articles77

More Articles
Development and validation of a new stability indicating reversed phase liquid chromatographic method for the determination of prednisolone acetate and impurities in an ophthalmic suspension.

J. Pharm. Biomed. Anal. 102 , 261-6, (2015)

A new stability indicating reversed phase high performance liquid chromatography (RP-HPLC) method was developed and validated under current International Conference of Harmonisation (ICH) guidance for...

Convenient QSAR model for predicting the complexation of structurally diverse compounds with β-cyclodextrins

Bioorg. Med. Chem. 17 , 896-904, (2009)

This paper reports a QSAR study for predicting the complexation of a large and heterogeneous variety of substances (233 organic compounds) with beta-cyclodextrins (beta-CDs). Several different theoret...

Investigation of Overrun-Processed Porous Hyaluronic Acid Carriers in Corneal Endothelial Tissue Engineering.

PLoS ONE 10 , e0136067, (2015)

Hyaluronic acid (HA) is a linear polysaccharide naturally found in the eye and therefore is one of the most promising biomaterials for corneal endothelial regenerative medicine. This study reports, fo...

 Synonyms

Pregna-1,4-diene-3,20-dione, 21- (acetyloxy)-11,17-dihydroxy-, (11β)-
(11b)-21-(Acetyloxy)-11,17-dihydroxypregna-1,4-diene-3,20-dione
acétate de 2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-diméthyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodécahydro-3H-cyclopenta[a]phénanthrén-17-yl]-2-oxoéthyle
Scherisolon
EINECS 200-134-1
Prednisolone acetate
11b,17,21-Trihydroxypregna-1,4-diene-3,20-dione 21-acetate
Ak-Tate
Pregna-1,4-diene-3,20-dione, 11β,17,21-trihydroxy-, 21-acetate (8CI)
Prednisolone-21-acetate
MFCD00037710
Deltacortenolo
(11β)-11,17-Dihydroxy-3,20-dioxopregna-1,4-dien-21-yl acetate
2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl acetate
2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-Dihydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxoethylacetat
Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-, (11β)-
Hydrocortidelt